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Thyroid hormones (THs) are essential for normal vertebrate devel-
opment. In mammals, including humans, precise levels of THs 
during fetal and neonatal life are critical for appropriate cell pro-
liferation and differentiation (1). Reduced or excessive THs during 
these developmental stages can result in severe abnormalities (2, 
3). Particularly dramatic is the observation of important altera-
tions in the maturation and function of the CNS in mammals with 
congenital hypothyroidism (2, 3). Some of the important actions 
of THs during development occur at a time when TH levels are 
much lower than those in the mother (4, 5) and the hypothalamic-
pituitary-thyroid (HPT) axis is not fully functional.
Type 3 deiodinase (D3), a conserved selenoprotein coded by the 
Dio3 gene, is responsible in part for the low TH levels in the fetus. 
Dio3 is subject to genomic imprinting and is preferentially expressed 
from the paternal allele in the mouse fetus (6, 7). D3 catalyzes the 
conversion of the hormones secreted by the thyroid, the active 
hormone 3,5,3′-triiodothyronine (T3) and prohormone 3,5,3′,5′-
tetraiodothyronine (T4), into biologically inactive metabolites by 
removing an iodine atom from the tyrosyl ring of both compounds 
to form 3,3′-diiodothyronine (3,3′-T2) and 3,3′,5′-triiodothyronine 
(reverse T3) (8, 9). Thus, D3 is an inactivator of THs and serves as a 
modulator of intracellular TH levels and TH action.
In rodents, D3 activity is abundant in the pregnant uterus and 
placenta (10–13) and most fetal tissues (14), including the CNS 
(15). In contrast, during late neonatal and adult life, D3 activity 
is more limited, being significant in the skin (16) and central ner-
vous system (15, 17, 18), detectable in certain endocrine organs 
(18), and very low or absent in other tissues.
Though the physiological significance of D3 is unknown, its 
biochemical function and tissue expression pattern suggest that it 
plays a role in protecting tissues, particularly those in the develop-
ing fetus, from inappropriate levels of THs. This is of particular 
importance as fetal serum levels of THs in the rat are only 5% of 
those present in the mother (19). As the HPT axis matures dur-
ing late gestation and the neonatal period, serum TH levels rise 
steadily and reach values comparable to those in the adult in the 
second week of life (5, 19).
In order to characterize the physiological relevance of D3, we 
have disrupted the gene coding for D3 in mouse embryonic stem 
cells and generated a D3 KO mouse (D3KO) with no detectable 
D3 activity. The D3KO mouse manifests marked abnormalities in 
thyroid status and physiology, underscoring the critical role of this 
enzyme in the development and function of the HPT axis.
Results
Neonatal hypothalamic D3 expression. To understand the potential role 
of D3 in the developing HPT axis, we first determined D3 activity in 
the mouse hypothalamus during neonatal life. We observed a high 
level of expression during the first week of life, with a marked dimi-
nution immediately thereafter (Figure 1). This pattern is similar to 
that described in the rat (20) and suggests a role for D3 in limiting 
hypothalamic exposure to THs during early development.
Generation of D3-deficient mice. We have recently described a suc-
cessful strategy utilizing homologous recombination in mouse ES 
cells for disruption of the Dio3 gene (6). The neomycin cassette 
used for positive selection of recombinant ES cells was excised with 
appropriate breeding with a Cre-expressing mouse as described in 
Methods. After this excision, the final structure of the mutated 
Dio3 locus is illustrated in Figure 2A. The mutant mice carry a 
triple point mutation affecting 2 codons, one of them coding for 
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selenocysteine, an active site residue that is critical for enzyme 
function (8, 21). That this construct codes for an inactive enzyme 
was shown by transfection experiments in COS-7 cells (data 
not shown), indicating that the mutation completely abolished 
enzyme activity. In addition to the triple mutation, mutant mice 
carry a residual insertion of a loxP site, 34 bp in length, located in 
the 3′-untranslated region. The presence of this insertion was used 
for routine genotyping as illustrated in Figure 2B.
This targeting strategy was designed to fully inactivate D3 while 
at the same time producing a minimal disruption in the Dio3 locus. 
This is critically important for 2 reasons. First, this locus is imprint-
ed and belongs to a larger imprinted domain in which long-range 
mechanisms may control gene expression (22, 23). Second, an addi-
tional gene, termed Dio3os, is expressed from the opposite DNA 
strand and features multiple transcripts that result from alternative 
splicing (6, 24). The full structure and function of the Dio3os gene 
have not yet been determined, but partial exonic sequences from 
a specific Dio3os transcript lie within the Dio3 exon and promoter, 
5′ to the point mutations and the residual loxP site (24).
Thus, a large deletion in the Dio3 locus might result in unwanted 
effects in gene expression within this imprinted region or in the 
disruption of Dio3os gene expression. To confirm that this was 
not the case, we performed Northern blot analysis to determine 
Dio3os mRNA expression in fetuses homozygous for the Dio3 
mutation. As shown in Figure 2C, there is no noticeable change in 
the pattern of Dio3os transcripts, suggesting that the small modi-
fications introduced in the Dio3 locus do not disrupt the expres-
sion of Dio3os transcripts in these mice. This is consistent with 
our previous observations that no Dio3os transcripts are detected 
by Northern blot analysis when using as a probe a genomic frag-
ment comprising the Dio3 3′-untranslated region (24), where the 
residual loxP site is located. Although it is uncertain whether the 
triple point mutation introduced in the Dio3 coding region lies 
within exonic sequence of the Dio3os gene, this mutation would 
not disrupt any of the potential open reading frames coding for a 
hypothetical Dio3os protein.
D3 activity is undetectable in D3KO mice. Unless stated otherwise, all 
the WT and D3KO animals (homozygous for the mutated allele) 
used in the present work were born to heterozygous mothers of the 
129/Sv strain. D3 activity in WT and D3KO mice was determined 
in various tissues known to express D3, such as the pregnant uter-
us, placenta, adult midbrain, cerebral cortex and ovary and in E14.5 
whole fetuses (Table 1). As expected, no D3 activity was detected in 
tissues from D3KO mice except in the placenta. Low levels of D3 
activity (2.5% of that in the WTs) were measured in the placentas 
of D3KO fetuses that were conceived by heterozygous mothers. 
This can be attributable to the presence in the tissue of a residual 
cell population of maternal origin that expresses D3. Indeed, no 
placental D3 activity was found in D3KO fetuses that were carried 
by D3KO mothers (Table 1). These results demonstrate that the 
introduced mutation completely inactivates the D3.
General phenotype of the D3KO mouse. The proportion of D3KO 
pups obtained from heterozygous matings was lower than the 25% 
expected from Mendelian laws. Out of 349 newborns produced 
from heterozygous parents, only 61 (17.5%) were D3KO (P = 0.05). 
This observation suggests partial lethality of D3KO mice that 
occurs at or before the time of birth. D3-deficient mice also exhib-
ited impaired reproductive function. Fertility rates were very low 
in D3KO mice of both sexes. In addition, both male and female 
D3KO mice were markedly growth retarded (Figure 3). This retar-
dation was already apparent at weaning, when their weight was 
only 65% of that of the WT mice. This reduction in size persists 
into adulthood and is still observed in 1-year-old animals (data not 
shown). Body length is approximately proportional to weight, as 
shown in the picture included in Figure 3. This general phenotype, 
with slight variations, is observed in 129/Sv, C57BL/6, and mixed 
129/Sv/C57BL/6 genetic backgrounds.
Weanling and adult D3KO mice manifest central hypothyroidism. In the 
late postnatal period, D3KO mice were hypothyroid. Compared 
with WT mice, the serum T4 level in D3KO weanlings was reduced 
Figure 1
Neonatal hypothalamic D3 activity. Each point represents the mean ± 
SEM of determinations in 4 animals.
Figure 2
Targeting of the Dio3 locus. (A) Diagram of the modified Dio3 exon 
after gene targeting and neomycin cassette excision. The triple point 
mutation introduced into the D3 catalytic site as well as the location 
of the PCR primers P1 and P2 used for genotyping are shown. (B) 
Typical results from PCR genotyping of WT, heterozygous (het), and 
homozygous mice using the primers P1 and P2. (C) Dio3os mRNA 
transcripts expressed in WT and D3KO E15.5 fetuses. Thr, threonine; 
Secys, selenocysteine.
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by more than 95%, and the serum T3 concentration was reduced 
by 50% of normal. However, the serum thyroid-stimulating hor-
mone (TSH) level was unaffected (Figure 4A). In adult D3KO mice, 
serum T4 and T3 levels were also low (27% and 80% of those in 
WT animals, respectively) while the serum TSH level was elevated 
50% (Figure 4B). A very similar pattern of thyroid parameters was 
observed in older adults (Figure 4C), indicating that the central 
hypothyroidism persists through adult life. The increase in the 
TSH level in adults was much lower than what would be antici-
pated, given the low circulating levels of THs. As a comparison, 
a 90-fold increase in TSH concentrations has been observed in 
mice in which comparably low TH levels were induced by feeding 
a low-iodine diet containing propylthiouracil (25). This failure 
of the serum TSH level to be elevated appropriately in the face of 
low circulating T4 and T3 levels points to a central etiology of the 
hypothyroidism. Values for T3 uptake were comparable in WT and 
D3KO mice, 60.1 ± 1.2 and 60.7 ± 1.2, respectively, suggesting that 
free fractions of T4 and T3 are the same in the 2 strains.
These low serum TH levels observed in adult D3KO mice 
resulted in tissue hypothyroidism. Thus, hepatic expression of 
TH-inducible genes such as spot 14 (S14) (26) and type 1 deio-
dinase (D1) (27) was significantly decreased. Liver S14 mRNA 
expression was reduced by more than 80% in D3KO mice, both in 
adults and weanlings (Figure 5A). D1 activity and mRNA were also 
diminished in D3KO weanlings (Figure 5B).
Perinatal D3KO mice are thyrotoxic. In contrast to the hypothy-
roidism present in adult mice, D3KO neonates were thyrotoxic, 
based on a markedly elevated serum T3 level. At P5, the serum 
T3 level in D3KO mice was elevated 4-fold compared with that 
of WT animals (Figure 6A). By P10, the serum T3 level in WT and 
D3KO mice was comparable, and then, during the next 11 days of 
life, D3KO mice transitioned to the hypothyroid state observed in 
weanlings and adults. Thus, at P15, the serum T3 level in D3KO 
mice was significantly lower (Figure 6A) and by day 21 was only 
50% of that observed in WT mice. It is notable that through-
out the same period, serum T4 levels in D3KO mice were barely 
detectable and much lower than in WT mice (Figure 6B). In WT 
mice, the serum T4 level increased steadily during neonatal life to 
reach a peak around P15. No such neonatal T4 surge occurred in 
D3-deficient animals.
D3KO mice were also thyrotoxic in utero and at the time of 
birth; compared with WT mice, E19.5 D3KO fetuses and 1-day-
old neonates showed a several-fold elevation in the serum T3 level 
(Figure 6A). At these stages, serum T4 levels were undetectable 
(<0.15 µg/dl) in both mutant and WT mice (Figure 6B).
Neonatal serum TSH was markedly suppressed in D3KO mice. In 
WT animals, serum TSH values (in mU/l) were 76.8 ± 13.5 (n = 8), 
47.3 ± 7.7 (n = 7), and 30.5 ± 8.0 (n = 5) at P5, P10, and P15, respec-
tively. In contrast, serum TSH in D3KO mice at the same ages was 
undetectable (<10 mU/l in the assay, n = 5, 3, and 3 animals in each 
age group, respectively). Figure 6C summarizes the changes in thy-
roid parameters that occurred in D3KO mice through 90 days of 
age, expressed as a percentage of the values determined in WT ani-
mals. This panel shows 3 phases in the abnormalities of the D3KO 
thyroid axis. D3KO mice were thyrotoxic early in life with markedly 
elevated serum T3 and suppressed serum T4 and TSH. At day P15, 
a pattern of central hypothyroidism is apparent with low T4, T3, 
and TSH. After weaning and into adulthood, TSH became mildly 
elevated though the central hypothyroidism persisted.
To gain further insight into the cause of the high T3 levels 
observed during the perinatal period in D3KO mice, we evaluated 
the rate of T3 clearance from the serum. WT and D3KO 2-day-
old pups were injected with a tracer amount of [125I]-T3, and the 
[125I]-T3 present in the blood was measured at different times. Two 
hours after injection, the level of [125I]-T3 in the serum of D3KO 
pups was double that in the WT mice (Figure 7A). Seven hours 
after injection, [125I]-T3 had decreased significantly in WT pups 
but very little in the D3KO pups. From the slopes of the curves, 
we estimated that D3KO newborns exhibited a significant reduc-
tion in the serum T3 clearance rate. Serum [125I]-T3 in WT mice 
decreased approximately 5 times faster than in D3KO animals. 
Small amounts (<5% of the total) of other radioactive metabolites 
were noted in the serum of injected animals. In addition, values 
for serum T3 uptake were comparable in WT and D3KO mice at 
P2 (Figure 7B), suggesting no difference in serum binding of T3 
between the 2 strains. Thus D3KO neonates demonstrate a dimin-
ished T3 clearance, and this likely plays an important role in the 
high serum level of T3 observed at this age.
Brain thyrotoxicosis in D3KO neonates. To determine the effects on 
the brain of the elevated serum T3 level during the neonatal peri-
Table 1
D3 activities in different tissues of WT and D3KO mice
Tissue	 WT	 D3KO
Pregnant uterus 12402 ± 552 Undetectable
E14.5 fetus 988 ± 92 Undetectable
Adult cortex 1024 ± 42 Undetectable
Rest of adult cerebrum 1066 ± 102 Undetectable
Adult ovary 73 ± 3 Undetectable
Placenta (heterozygous mother) 3070 ± 267 77 ± 6
Placenta (D3KO mother)  Undetectable
D3 activities (fmol/h/mg protein) represent the mean ± SEM. Uterus and 
placenta samples correspond to E17.5 gestational age. Adult tissues 
were obtained from 3-month-old mice. From 4 to 6 samples were used 
for each determination. Undetectable activities in the assay conditions 
were lower than 2 fmol/h/mg protein.
Figure 3
Postweaning growth curves of WT and D3KO male mice. Each point 
represents the mean ± SEM of measurements recorded in 7 to 58 
animals at each age. Mean and median group size per data point were 
18 and 12, respectively. Only data from animals born in litters of 3 to 7 
pups are included. Data from extremely growth retarded D3KO mice, 
which typically do not survive through weaning, are not included. A 
picture of representative WT and D3KO weanlings is shown. Body 
length appear to be proportional to body weight.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 116   Number 2   February 2006 479
od, we analyzed the mRNA expression of RC3 and hairless, 2 genes 
that are upregulated by THs in the CNS during the neonatal peri-
od (28, 29). In 1- to 3-day-old total brains, hairless expression was 
significantly elevated in D3KO animals (Figure 8A). The hairless 
mRNA level in the hypothalamus of D3KO mice was also mark-
edly elevated at P5 (Figure 8A). These observations indicate that 
the elevated serum T3 level is accompanied by enhanced T3 action 
in the neonatal brain. Indeed, the T3 concentration in the brains 
of D3KO neonates at P2 was more than double that in WT mice 
(Figure 8B). At P3, RC3 mRNA expression was also stimulated in 
the brain of D3KO mice as compared with that of WT mice (Figure 
8C), but its expression was lower than normal by P15 (Figure 8C), 
following the onset of central hypothyroidism. These results indi-
cate that the brain evolves from a thyrotoxic state in the newborn 
to a hypothyroid state in late neonatal life, undergoing a transition 
in thyroid status analogous to that observed in serum.
An important factor regulating TH action in the brain is type 
2 deiodinase (D2), an enzyme that converts the prohormone T4 
into the active hormone T3 (8, 9). D2 protects the brain from low 
levels of THs, and its activity is markedly increased when T4 lev-
els are low (8, 30). In the present study, the profile of D2 activity 
in the brain of D3KO mice was consistent with the observed low 
serum T4 level. Thus, D2 activity was significantly elevated in the 
cerebral cortex of D3KO mice on P5 (Figure 8D) and was dramati-
cally elevated (10- to 15-fold higher than in WT mice) from P10 
to P21. A significant increase in D2 activity was also found in the 
adult cortex at P90.
Thyrotropin-releasing hormone expression and hypothalamic T3 content. 
To investigate the nature of the central hypothyroidism found in 
weanlings and adult D3KO mice, we measured hypothalamic T3 
content and thyrotropin-releasing hormone (TRH) mRNA expres-
sion. At 15 days of age, no difference was observed in the T3 con-
tent of the hypothalamus between WT and D3KO mice (Figure 
9A). However, a moderate but significant decrease in the T3 con-
tent was observed in the hypothalamus of adult D3KO mice. No 
difference in TRH mRNA was observed at P15 (Figure 9B), but 
TRH expression was elevated in adult D3KO mice, consistent with 
the diminished hypothalamic T3 content observed at this age.
Discussion
We have found that mice lacking an active D3 exhibit a number of 
abnormalities, including partial perinatal mortality, growth retar-
dation, and impaired fertility. D3-deficient neonatal mice also 
manifest decreased T3 clearance and striking alterations in serum 
and tissue TH levels during perinatal life and adulthood. Thus, 
Figure 4
Thyroid status of D3KO mice. Serum T4, T3, and TSH levels in 
(A) weanlings (21 days old), (B) adults (90 days old), and (C) older 
adults (8 to 13 months old). Number of animals tested are indicated 
in parentheses. Bars represent the mean ± SEM. †P < 0.05; #P < 0.01; 
*P < 0.0001, WT versus D3KO.
Figure 5
Expression of hepatic T3-inducible genes. (A) Representative North-
ern blot analysis of liver S14 mRNA in 21-day-old weanlings and 
90-day-old adults (top panels) and quantification of S14 mRNA (bottom 
panel). 15 µg of total RNA were used. For each sample, the number 
of different animals is indicated in parentheses. (B) Expression of D1 
mRNA (left panels) and activity (right panel). In Northern blot analysis, 
3 µg of poly (A)+ RNA were used. Bars represent the mean ± SEM. 
Number of determinations are indicated in parentheses. *P < 0.0001, 
WT versus D3KO. Cy, cyclophilin.
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our findings in this new mouse model indicate that D3 is critical 
for both normal development and function of the thyroid axis.
We have shown that the D3KO mouse has no detectable D3 
enzymatic activity and that the pattern of transcripts for the 
Dio3os gene that is transcribed from the opposite strand at the 
Dio3 locus does not appear to be disrupted. Thus, the abnormali-
ties observed in the D3KO mice likely are due solely to the absence 
of an active D3 enzyme.
Our observations indicate that the lack of D3 results in a mark-
edly elevated level of T3 in the serum of fetuses and early neonates. 
As it is during this developmental stage that D3 expression is at 
its highest in the hypothalamus and in most tissues, our results 
demonstrate that D3 plays a critical role in maintaining low levels 
of THs during fetal and early neonatal life. In the absence of D3, 
the clearance of T3 is diminished, and this likely contributes to the 
perinatal thyrotoxicosis observed in D3KO mice. In addition to an 
increased serum T3 level, increased T3 action in the brain and the 
hypothalamus is also observed. In the normal brain, the expression 
of various T3-inducible genes increases steadily at a well-defined 
rate during neonatal life (31). However, in the D3-deficient new-
born, this developmental pattern of expression is disrupted; the 
expression of T3-responsive genes is higher than normal at early 
neonatal ages and then lower than normal later in development. 
The functional consequences of this altered gene expression pat-
tern are as yet undefined but likely to be significant.
The thyrotoxic status in the D3KO newborn evolves to hypo-
thyroidism after 2 weeks of life, and this persists in adulthood. 
This is accompanied by tissue hypothyroidism, as demonstrated 
by a marked decrease in liver expression of T3-inducible genes. The 
nature of this hypothyroidism is clearly central, as serum TSH is 
suppressed, unchanged, or only slightly elevated in D3KO at dif-
ferent stages despite the low serum concentrations of both T4 and 
T3. In the adult, a 50% increase in TSH is observed in the presence 
of low T4 and T3 levels. However, this TSH elevation is very mod-
est compared with a model of primary hypothyroidism that shows 
similar serum TH levels (25) and where TSH levels are increased 
90-fold. This comparison indicates that the hypothyroidism in 
D3KO mice is due to central abnormalities of the HPT axis. Indeed, 
the TH parameters in the D3KO mouse are remarkably similar to 
those observed in the TRH and TRH-receptor KO mouse models 
(32, 33), where serum T4 and T3 are decreased and serum TSH is 
modestly elevated or unchanged, respectively.
In the adult D3KO mouse, the inability of increased TSH levels 
to normalize TH concentrations may reflect a defect in the thyroid 
gland. Although this possibility cannot be discarded, preliminary 
observations indicate that the size and appearance of the thyroid 
gland is normal. A more plausible explanation for the lack of TSH 
effect is that TSH bioactivity is diminished. TRH signaling is criti-
cal for the proper maturation and glycosylation of TSH (34, 35), 
and these posttranslational modifications have been shown to be 
necessary for full TSH bioactivity in human cases of central hypo-
thyroidism of hypothalamic origin (36). This has also been shown 
in the TRH KO mouse (37).
In considering the etiology of the central hypothyroidism in the 
adult D3KO mouse, the rodent model referred to as the neonatal 
T4 (neo-T4) syndrome may be of relevance (38, 39). In this model, 
the injection of pharmacological doses of T4 (or T3) to rats for 3 
to 5 days immediately after birth results in the development of 
central hypothyroidism in adults. These animals also show an 
Figure 7
Neonatal serum T3 clearance and uptake. (A) [125I]-T3 levels in 2-day-
old newborn mice after a single intraperitoneal injection of [125I]-T3 (see 
Methods). (B) Percentage of T3 uptake by serum from 2-day-old neo-
nates. Each point represents the mean ± SEM of determinations in 4 
(A) and 7 (B) animals in each group. *P < 0.0001, WT versus D3KO.
Figure 6
Ontogeny of serum T3, T4, and TSH. (A) Perinatal serum T3 levels. 
(B) Perinatal serum T4 levels. T4 levels were undetectable (<0.1 µg/dl) 
in E19.5 fetuses and P1 neonates of both genotypes as indicated by 
the dotted line. Each point represents the mean ± SEM of determina-
tions in 6 (A) and 7 (B) animals in each group. *P < 0.0001, WT versus 
D3KO. (C) Ontogeny of T3, T4, and TSH serum levels expressed as a 
percentage of the values in WT animals of corresponding age. Serum 
TSH was undetectable in D3KO mice between 5 and 15 days of age 
(see text for absolute TSH values).
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impaired pituitary response to TRH (40, 41). Thus, the neo-T4 rat 
model demonstrates that exposure to inappropriately high levels 
of THs before the HPT axis is functionally mature results in pitu-
itary and/or hypothalamic abnormalities that affect its regulatory 
mechanisms and set point.
Similar observations have been made in humans. Several articles 
have described infants who experienced thyrotoxicosis in utero as 
a result of poorly controlled maternal hyperthyroidism and who 
subsequently developed transient neonatal central hypothyroid-
ism (42, 43). In view of these observations, we suggest that the 
main cause of central hypothyroidism in D3KO mice is their over-
exposure to T3 during a critical period of thyroid axis develop-
ment. The molecular parameters mediating this occurrence have 
not been identified in any of these models.
Notably, the central hypothyroidism observed in D3KO mice is 
more severe than that in neo-T4 rats whereas in the human cases 
mentioned above, the central hypothyroidism appears to be tran-
sient. Although common mechanisms may cause the abnormali-
ties of the HPT axis in the 3 models, the increased severity of the 
D3KO phenotype may be due to a higher degree and/or longer 
duration of tissue T3 overexposure. In this regard, it 
is worth noting that both the neo-T4 rats and human 
infants born to hyperthyroid mothers have functional 
D3 that may be upregulated in the face of hyperthy-
roidism (44) and thus partially protect the brain from 
exposure to high TH levels. D3KO mice have no such 
protective mechanism to ameliorate overexposure to T3. 
Hence, a more severe phenotype is not unexpected.
D3KO mice possess intact TRH and TRH-receptor 
genes and, indeed, TRH expression is increased in the 
adult D3KO hypothalamus, presumably in response 
to the demonstrated decrease in T3 content. Thus, 
D3 deficiency does not lead to excessive T3 effects 
(e.g., suppression of TRH) in the hypothalamus of the 
adult D3KO animal. This observation implies that the 
mechanism or mechanisms responsible for TSH dys-
regulation in the D3KO animal differ fundamentally 
from that of the TRH KO animal and involve other 
molecular changes that alter the set point of TSH secretion 
in response to TH feedback. Of interest in this regard is that 
THs are known to regulate TRH-receptor mRNA levels in the 
pituitary gland, and conceivably this could be part of a develop-
Figure 8
Brain expression of T3-regulated genes. (A) Expression of 
hairless in the newborn brain and neonatal hypothalamus. 
Representative Northern blots are shown, and quantification 
of expression was performed in the number of animals indi-
cated in parentheses. Each bar represents the mean ± SEM. 
Ribosomal staining or cyclophilin expression was used as a 
control to correct for the amount of RNA loaded per lane. (B) 
Brain T3 content of P2 newborns. (C) Northern blot analy-
sis of RC3 expression in the brain at P3 and P15. The most 
abundant RC3 transcript is shown. (D) Neonatal and adult 
brain D2 activity. Each point represents the mean ± SEM of 
determinations in 6 animals. *P < 0.0001, WT versus D3KO.
Figure 9
Hypothalamic T3 content and TRH mRNA expression. (A) Hypotha-
lamic T3 content as determined by RIA in hypothalami of 15-day-old 
and adult (3-month-old) mice. (B) Quantitation of Northern blot analy-
sis of hypothalamic TRH mRNA levels in 15-day-old and adult mice. 
Each bar represents the mean ± SEM of determinations in 5 animals. 
*P < 0.001, WT versus D3KO.
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mental program to determine the set point of the thyroid axis 
control mechanisms (45).
The thyroid status of the D3KO hypothalamus at P15 does not 
reflect the circulating low TH levels; the T3 content of the hypo-
thalamus is not different from that observed in WT mice despite 
significant decreases in serum T3 and T4 levels. This is possibly 
due to the marked increase in D2 activity or the fact that the brain 
is still evolving from a thyrotoxic state and has yet to adjust to 
lower serum TH levels. In the adult, however, the thyroid status 
of the hypothalamus in the D3KO mouse reflects the hypothy-
roid serum levels and results in a modest increase in TRH mRNA 
expression that qualitatively mimics the situation in WT animals 
(46). This finding of a relatively small increase in TRH expression 
might be due to the fact that only a fraction of hypothalamic neu-
rons display T3-sensitive TRH expression (45).
Other phenotypic abnormalities observed in the D3KO mouse 
include impaired growth, low fertility, and partial perinatal lethal-
ity. It is well established that THs exert profound effects on growth 
hormone expression (47). Thus, alterations in the growth hormone 
axis may play a role in the growth retardation observed in D3KO 
mice. Impaired viability in D3KO mice may be due to perinatal 
thyrotoxicosis, as a similar observation has been made in rats and 
humans (48, 49). Concerning the reproductive function of the 
D3KO mouse, severe hypothyroidism may affect fertility in both 
sexes, as demonstrated by hyt/hyt mice (50, 51). Of note, fertility 
in the TRH KO mouse, which manifests a milder degree of hypo-
thyroidism that is similar to that in the D3KO mouse, is normal 
(32). Thus, factors in addition to alterations in adult thyroid sta-
tus likely play a role in the impaired fertility of the D3KO mouse. 
For instance, in utero thyrotoxicosis may also contribute to the 
perceived lower fertility of D3KO female mice, as the absence of 
a functional maternal D3 in tissues involved in implantation and 
placentation may be detrimental to early embryonic viability.
In summary, our results demonstrate that D3 is critical for the 
normal development and function of the thyroid axis and plays a 
role in maintaining appropriate TH levels in the fetus and neonate. 
D3 may be expressed to lower T3 content in this region such that 
the thyroid axis set point can develop normally. Beyond the neo-
natal period, the rapid decrease in D3 activity allows the hypothal-
amus to more accurately track serum TH levels and thus adjust 
TRH expression appropriately.
Although a D3 deficiency has not yet been reported in humans, 
the observations in the D3KO mouse predict the occurrence of 
central hypothyroidism as part of the phenotype in such cases. 
This new model of central hypothyroidism will be valuable for 
analyzing the events regulating the maturation and function of 
the thyroid axis, as well as the role of D3 and THs in the physiology 
of growth, development, and reproduction.
Methods
Generation of D3KO mice. We recently described (6) the strategy used to target 
the Dio3 gene using standard homologous recombination techniques. We 
utilized the R1 ES cell line (52), which originated from the 129/Sv mouse 
strain. Targeted clones were identified by Southern blot analysis, injected 
into C57BL/6 blastocysts, and reimplanted in CD1 foster mothers. Chimeric 
males that showed germ-line transmission were mated to C57BL/6 females 
to test for germ-line transmission of the mutation. Chimeric males were 
then mated with 129/Sv females to establish the mutant line in a 129/Sv 
background. The neomycin cassette was excised by mating heterozygous 
females with a 129/Sv male carrying in chromosome X a transgene express-
ing the Cre DNA recombinase. The removal of the neomycin cassette was 
confirmed by Southern blot analysis in the first generation females. The 
Cre DNA recombinase transgene was removed from the genetic back-
ground of the colony by appropriate matings with WT 129/Sv animals and 
sex selection. Animals were kept under a 12-hour light cycle and provided 
food and water ad libitum. Animal procedures were approved by the Dart-
mouth College Institutional Animal Care and Use Committee.
Mice genotyping and serum and tissue sampling. After the removal of the neo-
mycin cassette, genotyping of mice carrying the inactivating mutation was 
performed by PCR amplification of the residual loxP site (Figure 1). The 
primers used were as follows: 5′-GGAGTCCTGCTGCTTTTGTG-3′ (sense); 
5′-CGAGCCTCTCTGCAATTCAG-3′ (antisense). The PCR protocol consist-
ed of 32 cycles that included 20 seconds at 94°C, 20 seconds at 60°C, and 
45 seconds at 72°C, with a final extension of 3 minutes. Mouse DNA was 
isolated by standard procedures after proteinase K digestion of tail snips.
Animals were killed by asphyxiation with CO2 (adults and weanlings) or 
by decapitation (neonates). In the adults and older neonates, blood was 
taken from the inferior vena cava while trunk blood was collected from 
younger neonates and fetuses. Serum was obtained by centrifugation and 
stored at –20°C. For Northern blot analysis and enzymatic activity, tissues 
were dissected, immediately frozen on dry ice, and stored at –70°C. Whole 
hypothalami were dissected, considering the midbrain and thalamus as the 
posterior and dorsal limits, respectively, and the optic chiasm and its ends 
as the anterior and lateral limits, respectively.
For the serum determination of T3 clearance, 2-day-old neonates were 
injected intraperitoneally with a trace amount of [125I]-T3 (New England 
Nuclear) (150,000 cpm, approximately 100 fmol in a volume of 50 µl). 
Trunk blood was collected at 2 and 7.5 hours after injection and centri-
fuged to obtain the serum that was then subjected to paper chromatog-
raphy to separate T3 from other radioactive metabolites as described (18). 
The amount of radioactivity attributable to T3 was determined with a 
gamma counter. The clearance rate of T3 in serum was estimated from the 
slopes of the lines obtained by plotting the amount of residual [125I]-T3 
against the time after injection. The amount of [125I]-T3 injected was not 
corrected by body weight, as at 2 days of age the weight of D3KO mice is 
within 10% of that in WT animals.
D1, D2, and D3 activities. D1, D2, and D3 enzymatic activities were deter-
mined as previously described (18, 44). In brief, tissues were homogenized 
in a 10 mM tris-HCl, 0.25 sucrose pH 7.5 buffer. A suitable volume of tissue 
homogenate was used in the enzymatic reaction to ensure that deiodin-
ation did not exceed 20% and was proportional to the amount of protein 
content. Tissue homogenates were incubated at 37°C for an hour with 
the appropriate [125I]-labelled iodothyronine (New England Nuclear). For 
the D1 assay, 400 nM of reverse T3 in the presence of 2 mM of the cofac-
tor DTT were used. For the D2 assay, we used 1 nM T4 and 20 mM DTT. 
For the D3 assay, 2 nM T3 and 20 mM DTT were used. Deiodination was 
determined based on the percentage of labeled iodine released (D1 and D2 
assays) or the amount of [125I]-3,3′-diiodothyronine produced (D3 assay). 
The latter was determined after separation of reaction products by paper 
chromatography, as described (53). A factor of 2 was included in the cal-
culations of D1 and D2 activities to correct for the chemical equivalence 
of the outer ring iodine residues and the fact that only 1 of them is labeled 
in a given molecule.
RNA preparation and Northern blot analysis. Total RNA and poly (A+) RNA 
were isolated from mouse liver by guanidine hydrochloride and oligo-dT 
cellulose methods, respectively, following standard procedures (54). Total 
RNA was isolated from brain tissues using the Ribopure kit from Ambion 
Inc. Total and poly (A+) RNA samples were electrophoresed in a denatur-
ing 1% agarose gel containing formaldehyde and blotted onto a Nytran 
membrane (Schleicher & Schuell). Blots were hybridized at 42°C in buf-
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fer containing 50% formamide, washed with 0.1X SSC/0.1% SDS at 65°C, 
and autoradiographed for 1 to 7 days. Probes were labeled with radioactive 
32P-dCTP (ICN Biochemicals Inc.) using the Oligolabelling Kit (Pharma-
cia Corp.) and were purified through G-50 columns (Pharmacia Corp.). 
Quantification of mRNA bands was performed by computer-assisted 
densitometry (Molecular Dynamics). The mouse cDNA probes used were 
as follows: hairless, a 3-kb BamH1 fragment that includes most of the cod-
ing region; RC3, the complete 1.3-kb cDNA; TRH, a 0.8-kb PCR fragment 
that includes the coding region; S14, the complete 1.3-kb cDNA; D1, the 
complete 1.7-kb cDNA; Dio3os, a mix of 3 partial cDNAs with GenBank 
accession numbers AY283182, AY283181, and AY077459.
Hormone determinations. Serum total T4 concentration was determined 
using the total T4 Coat-a-Count RIA kit (Diagnostic Systems Laborato-
ries Inc.) according to the manufacturer’s instructions. The sensitivity of 
the assay as determined experimentally ranged from 0.1 to 0.2 µg/dl. The 
serum T3 level was determined using a sensitive RIA method established 
in our laboratory (55) with the modification that the T3 antibody used was 
obtained from a commercial source (Fitzgerald Industries International 
Inc.). An index of the circulating levels of TH carrier proteins was obtained 
by measuring the residual capacity of the serum to bind [125I]-T3, using the 
Coat-A-Count RIA T3 uptake kit (Diagnostic Systems Laboratories Inc.) 
according to the manufacturer’s instructions. For brain and hypothalamic 
T3 determinations, the tissue was weighed and homogenized in 2 ml of 
methanol containing 1 mM propylthiouracyl, centrifuged, and the pellet 
reextracted twice more. Methanol from the supernatants was collected and 
evaporated, the residue resuspended in a buffer containing 0.2 M glycine, 
0.13 M sodium acetate, and 0.02% bovine serum albumin, and analyzed by 
RIA. Recoveries were not considered for the calculations as they were deter-
mined to be higher than 95% by using a radioactive tracer. T3 was calcu-
lated as the average of determinations at 2 different dilutions that typically 
did not differ more than 15%. The cross reactivity of T4 with the T3 anti-
body was less than 0.38%. Adult and weanling serum TSH levels were deter-
mined using a highly sensitive double-antibody method developed by A.F. 
Parlow (56). Cross reactivity with follicle-stimulating hormone or luteiniz-
ing hormone was less than 1%. Neonatal serum TSH was measured in 50 µl 
of serum using a sensitive, heterologous, disequilibrium, double-antibody 
precipitation radioimmunoassay developed by Pohlenz et al. (57).
Statistics. Statistical significance between groups was determined by 
the 2-tailed Student’s t test. To assess the proportions of genotypes in 
the offspring from heterozygous matings, statistical significance was 
determined by the c2 test.
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